Ovarian hyperstimulation syndrome following the sole administration of injectable gonadotropin-releasing hormone agonist (triptorelin) for the pituitary down-regulation and in vitro fertilization treatment: report of two cases.
This report is to illustrate two cases of ovarian hyperstimulation syndrome following the sole administration of injectable mid-luteal gonadotropin-releasing hormone agonists (triptorelin) for pituitary down-regulation. Both women underwent egg retrieval, and despite the transfer of good quality embryos, no pregnancy was achieved. The possible mechanism and management of the condition were discussed.
Qublan
Hussein S
HS
Department of Obstetrics and Gynecology, IVF Center, Prince Rashed Hospital, Royal Medical Services, Irbid-Aidoun, Jordan. hqublan@yahoo.com
Beni-Merei
Zakarya
Z
Megdadi
Mohamad
M
Al-Quraan
Gassan
G
D000328:Adult; D004624:Embryo Transfer; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007246:Infertility / Q000628:therapy; D007986:Luteinizing Hormone / Q000097:blood; D006080:Ovarian Follicle / Q000000981:diagnostic imaging; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D011374:Progesterone / Q000097:blood; D017211:Treatment Failure; D017329:Triptorelin Pamoate / Q000009:adverse effects*; D014463:Ultrasonography
D017329:Triptorelin Pamoate; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone